Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
December 13, 2006

Ablynx Achieves First Milestone With P&GP

  • Ablynx reached a first milestone in its discovery and development collaboration with Procter & Gamble Pharmaceuticals (P&GP) establishing the potential of Ablynx’ Nanobody® technology for possible new treatments in the musculoskeletal category.

    The Nanobody® technology has been used to rapidly identify a highly diverse and potent panel of Nanobodies® against one of the targets exclusive to the collaboration, triggering a milestone payment. 

    As part of this on-going collaboration Ablynx is responsible for discovering Nanobodies® that meet an agreed product profile. P&GP is responsible for the pre-clinical and clinical development of Nanobodies® as well as the commercialization of any resulting drug products.

  • You’re all set! Thank you for subscribing to GEN Highlights.